FORM 10-C
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
Report by issuer of securities quoted on The Nasdaq Stock Market(sm), filed
pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 and Rule
13a-17 or 15d-17 thereunder.
EXACT NAME OF ISSUER AS SPECIFIED IN CHARTER: Aronex Pharmaceuticals, Inc.
----------------------------
ADDRESS OF PRINCIPAL EXECUTIVE OFFICES: 3400 Research Forest Drive, The
-----------------------------------
Woodlands, Texas 77381
- ----------------------
ISSUER'S TELEPHONE NUMBER (INCLUDING AREA CODE): (713) 367-1666
I. Change in Number of Shares Outstanding
Indicate any change (increase or decrease) of five percent or more in the number
of shares outstanding:
1. Title of security Common Stock
------------
2. Number of shares outstanding before the change 22,020,283
----------
3. Number of shares outstanding after the change 28,920,283 (as of May 30,
--------------------------
1996)
-----
4. Effective date of change May 22, 1996 (initial closing) and May 30, 1996
-------------------------------------------------
(over-allotment)
----------------
5. Method of change New issuance
------------
Specify method (such as merger, acquisition, exchange, distribution, stock
split, reverse split, acquisition of stock for treasury, etc.) Give brief
description of transaction Public offering of 6,900,000 shares of Common Stock
---------------------------------------------------
II. CHANGE IN NAME OF ISSUER
1. Name prior to change
2. Name after change
3. Effective date of charter amendment changing name
4. Date of shareholder approval of change, if required
May 31, 1996 /s/ Terance A. Murnane Controller and Secretary
- -------------------------------------------------------------------------------
DATE OFFICER'S SIGNATURE AND TITLE
